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Twenty-six years after the first human liver transplanta-
tion was performed in Denver, I the procedure has 
evolved into the preferred therapy for end-stage liver 
disease of various etiologies. A number of significant 
events have enabled this transformation of an experimen-
tal to a service procedure. These include the following 
four critical steps: 
1. The first use of cyclosporine in clinical trials in 
19792 and its systemic combination with steroids3 .4 were 
essential. The use of cyclosporine in combination with 
other immunosuppressive agents, that is, prednisone, 
azathioprine, and antilymphocyte globulin, resulted in 
markedly improved results in cadaveric renal and extra-
renal organ transplantation. 3-5 
2. The introduction and routine use of the veno-
venous bypass in 19836-8 made the procedure safer for 
the patient and technically easier for the surgeon. It has 
allowed for the training of a new generation of liver 
transplant surgeons. 
3. The National Consensus Meeting at the National 
Institutes of Health in 1983 determined that liver trans-
plantation was no longer an experimental, but rather a 
therapeutic procedure for a variety of chronic irreversible 
liver diseases. 9 This administrative blessing allowed the 
broad application of liver transplantation. 
4. A new preservation solution developed at the 
University of Wisconsin by Dr F. O. Belzer and associ-
ates became available in the fall of 1987.10 Safe preser-
vation of the liver for greater than 24 hours became 
possible. II Although the impact and revolutionary ef-
fects of this advance are immediately evident, their full 
extent has surely not as yet been appreciated. 
LIVER TRANSPLANTATION FOR PRIMARY 
BILIARY CIRRHOSIS 
One of the most favorable indications for liver 
transplantation has traditionally been cholestatic liver 
disease. 12 Primary biliary cirrhosis (PBC), one of the 
cholestatic syndromes, is the second most common in-
dication for liver transplantation in the adult,13,14 ac-
counting for 16.5% of all liver transplants performed. 
There are two reasons why liver transplantation is 
favored treatment for PBC. First, survival is substan-
tially better than that to be expected with conservative 
management. 12,13 Second, good health is restored with 
the operation. About 90% of the recipients transplanted 
for PBC have returned to their occupation at least part 
time. In contrast, the group of patients who stoically 
endure their disease are on a march to a miserable death. 
THE ISSUE OF RECURRENCE OF THE 
DISEASE AFTER TRANSPLANTATION 
The initial report of recurrence of PBC in three 
patients by Neuberger et al 15 was not confirmed in the 
Pittsburgh experience. 16 Recurrence of the disease, us-
ing the criteria described by Neuberger et aI, IS was not 
found by Demetris et al 17 in a recent pathologic review 
of graft specimens obtained from 106 patients with PBC. 
The antimitochondrial antibodies (AMA) usually re-
turned or never went away (see Berg and Klein in this 
issue of Seminars), but this was not reflected in the ho-
mografts. PBC-like changes were observed by the Cam-
bridge groupl8 in transplant patients who did not have 
the disease originally. An increased incidence of chronic 
rejection in the patients transplanted for PBC was noted 
by the Pittsburgh group, 17 but the significance of this is 
purely speculative. 
It is possible that the histopathologic changes of 
PBC or the natural course of the disease could be altered 
by treatment with cyclosporine. However, the study has 
never been done adequately. 
THE SUCCESS RATE 
From the Department of Surgery, University Health Center of 
Pittsburgh, University of Pittsburgh, and the Veterans Administration For 194 patients with PBC transplanted between 
Medical Center, Pittsburgh, Pennsylvania. 1973 and 1988 at the University of Colorado and the 
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FIG. 1. Five-year survival of patients with PBC treated with 
transplantation at the University of Pittsburgh. 
INFLUENCE OF TRANSPLANTATION 
ON SURVIVAL 
There is strong evidence that transplantation im-
proves the survival of patients with PBC. Results of 
transplantation for PBC in Cambridge and Pittsburgh 
have been compared with predicted survival calculated 
from a statistical model (see Grambsch et al in this issue 
of Seminars). In both centers the results suggest a sig-
nificant benefit from transplantation. 
The Cambridge Series 
The predicted survial of the first 29 patients (using 
the Cambridge model), who underwent liver transplan-
tation for PBC at Cambridge, King's College hospital, 
was compared with their actual survival after 
transplantation. 19 The comparison favored transplanta-
tion, even though the I-year survival in this group of 
transplant patients was only 25% 
The Pittsburgh Series, Judged with the 
Mayo Model 
The Mayo model is a recently developed statistical 
model that predicts survival in PBC patients who have 
not undergone transplantation. It uses five variables: 
age, total serum bilirubin and albumin, prothrombin 
time, and edema (see Grambsch et al in this issue of 
Seminars.) 
One hundred sixty-one patients with a median fol-
low-up of 25 months after transplantation were studied. 
Their actual survival, when compared with the predicted 
survival of a simulated control group using the Mayo 
model, was 76% versus 45% at 1 year, and 74% versus 
31% at 2 years. 20 
The transplant patients were further divided into 
three risk groups, and their survival was compared with 
the actuarial survival of simulated controls. The advan-
tage of transplantation was observed in all three 
groups. 20 
PROGNOSTIC VALUE OF THE 
PREOPERATIVE CLINICAL VARIABLES 
The Pittsburgh experience with 194 patients who 
underwent 230 liver transplantations for PBC between 
April, 1973, and June, 1988, was reviewed. Their ages 
ranged from 23.5 to 76.6 years (mean, 48.1 ± 9.5 SO). 
Eleven of the patients (5.7%) were males and 183 
(94.3%) were females. Survival was calculated at 1 year 
after transplantation. 
The clinical variables studied were: age, gender, 
time elapsed between diagnosis of the disease and trans-
plantation, previous surgery, pathologic staging, ascites, 
total bilirubin, prothrombin time, creatinine, liver 
weight, and encephalopathy. Groups were defined 
within the variables in order to allow analysis of the 
survival data. Survival curves and statistical analysis 
were calculated on an IBM-AT computer using BMOP 
software (Los Angeles, CA). 
The results are summarized in Table 1. A number of 
variables were found to have no prognostic significance. 
Thus, survival in patients with encephalopathy was 
69.6% versus 78.4% in those without. Gender also failed 
to influence survival: Of 11 male patients, 9 (81.8%) are 
alive as are 136 (74.3%) of the 183 females. Survival 
according to the time elapsed between diagnosis of PBC 
and transplantation is shown in Table 2. The known 
duration of the disease had no effect on survival after 
transplantation. Notable also is that patients older than 
h 21 50 years fared at least as well as t e younger group. 
TABLE 1. The Relationship of Clinical Variables 
to Survival 
Variable and Group No. Survival Significance 
Age (yr) 
>60 26 81.3% 
50-60 46 75.4% 
<50 100 72.5% 0.5787 
Previous surgery 
None 71 80.7% 
(R) Upper abdomen 36 67.9% 
Other 35 67.3 0.1220 
Pathologic staging* 
Stage 3 21 77.8% 
Stage 4 117 73.6% 0.8239-0.6453' 
Ascites 
Controlled 63 64.9% 
Uncontrolled 8 88.9% 
None 70 82.4% 0.0165 
Total bilirubin (mg/dl) 
>20 32 66.7% 
10-20 65 75.6% 
2-10 37 78.7% 
<2 8 88.9% 0.3857 
Prothrombin time (sec) 
>15 10 55.6% 
<15 129 77.2% 0.0826--0.0431 t 
Creatinine (mg/dl): 
>1.3 10 58.8% 
<1.3 128 76.6% O. 1859-0. 1059t 
Liver weight (native 
hepatectomy specimen) 
(% of body weight) 
>3.5 56 77.8% 
2.5-3.5 54 77.1% 
<2.5 31 66.0% 0.2900 
*No patients at stage 2 or 3 were transplanted at our center. 
tBefore the Yates correction. 
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TABLE 2. Survival According to the Time Elapsed 
Between the Diagnosis of PBC and Transplantation 
Years Elapsed No. Alive Dead Percent 
1 18 16 2 88.8 
2 14 8 6 57.1 
3 19 15 4 78.9 
4 26 20 6 76.9 
5 19 10 9 52.6 
6 14 9 5 64.2 
7 11 9 2 81.8 
8 17 15 2 88.2 
9 or more 48 38 10 79.1 
Comments 
Although none of these variables has a statistically 
significant predictive value, some groups appear to be 
associated with a poor survival, for example, patients 
with a total bilirubin greater than 20 mg/dl, prothrombin 
time greater than 15 seconds, serum creatinine above 1.3 
mg/dl, and a liver weight less than 2.5% of body weight. 
These patients usually had advanced disease, indicating 
the need for earlier treatment. 
REHABILITATION AFTER 
TRANSPLANTATION 
Of our 194 patients, 145 (74.7%) are currently 
alive. Of these, we have accurate follow-up data on re-
habilitation in 129: One hundred twelve patients (86.8%) 
enjoy full activity. Eleven patients (8.5%) have a some-
what restricted activity. The cause of the partial disabil-
ity is bone disease in nine, manifested either as frequent 
bone fractures or as severe back pain, and in two hyper-
tention and renal disease. Five patients (3.9%) are home-
bound. In two this is due to renal failure, probably a 
complication of cyclosporine; two are still recovering 
from transplantation; and one is recovering from a recent 
colon resection. 
One patient (0.8%) is currently hospitalized, await-
ing retransplantation. 
TECHNICAL PROBLEMS PARTICULAR TO 
LIVER TRANSPLANTATION FOR PRIMARY 
BILIARY CIRRHOSIS 
PBC is generally a disease regarded with special 
favor by liver transplant surgeons because transplanta-
tion is technically easy, particularly in the absence of 
previous upper abdominal surgery. 
Special care is required for the arterialization of the 
new Ii ver, because a high incidence of intimal dissection 
ofthe common hepatic artery has been observed. 22 If this 
occurs, alternate sites such as the celiac axis or aorta 
should be used. 23 
ROLE OF RETRANSPLANTATION 
Liver transplantation is occasionally followed by 
potentially fatal complications. The salvage role of re-
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transplantation in this setting cannot be over-
emphasized. 24 
In our series of 194 patients studied, 39 (20.1 %) 
required retransplantation and six required a third trans-
plant (3%). Of the retransplantations, 31 (79%) were 
perfornled during the first month after the original im-
plantation. The causes for retransplantation are shown in 
the Table 3. Overall survival after retransplantation was 
38.4%. Survival after the third transplantation was 
16.7% (one of six). Complete recovery was possible in 
14 (87.5%) of the 16 survivors. Two patients are home-
bound; one patient has marginal renal function, and the 
second patient is temporarily disabled due to a recent 
colon resection. 
EFFECT OF SUCCESSFUL LIVER 
TRANSPLANTATION ON THE 
COMPLICATIONS OF PRIMARY 
BILIARY CIRRHOSIS 
Encephalopathy 
This is usually reversed within hours after termina-
tion of anesthesia; occasionally, a longer period is re-
quired, depending on its degree and the early function of 
the graft. In fact, the mental condition of the patient 
immediately postoperatively is one of the best available 
indicators of graft function. 
Pruritus 
Pruritus disappears promptly after liver transplanta-
tion. 
Jaundice 
Fast reversal of jaundice is a reliable sign of good 
early graft function. It fades away completely, usually 
within 1 to 2 weeks, depending on its preoperative 
depth. 
Deep skin pigmentation is also reversible but re-
quiring a longer period, as long as a few months. 
Skin Xanthomas 
Skin xanthomas usually regress completely within a 
few weeks after transplantation. 
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Varices and Variceal Bleeding 
A healthy liver is a perfect portocaval shunt and 
dramatically stops variceal bleeding. On a few occa-
sions, we have encountered postoperative variceal bleed-
ing from very large gastric or intestinal varices that have 
required ligation. 
Ascites 
Ascites is cured at a rate depending on its preoper-
ative volume and the renal function. 
Splenomegaly 
Splenomegaly usually regresses within months. 25 
Immediately postoperatively, the enlarged spleen can be 
a source of infection, especially if the splenic artery has 
been ligated during the transplant procedure. 
Weight Loss 
Weight loss is usually replaced by the problem of 
weight control, which often occurs with return to good 
health. Prednisone is a significant contributing factor, 
although not as notable in the cyclosporine era since less 
of it is used. 
Muscle Wasting 
Restoration of the muscle mass can be complete but 
requires systematic physical therapy. The importance of 
the patient's motivation cannot be overemphasized in 
this part of rehabilitation because the effort is usually 
hampered by the often coexisting osteopathic pains. This 
bone pathologic condition must be considered during the 
rehabilitation. 
Osteoporosis and Osteomalacia 
Back and bone pains frequently regress immedi-
ately after transplantation, but improve as recovery pro-
ceeds. Severe osteopathy requires a very lengthy reha-
bilitation, is resistant to treatment, but has been shown to 
be reversible. 26 Calcium and vitamin D supplements are 
given empirically and the patients are alerted about the 
risk of fracture. If indicated, braces can be used. Despite 
all efforts, the pretransplant osteopathy can be a source 
of long-term disability after transplantation. 
TRANSPLANTATION OF MORE THAN ONE 
ORGAN IN PATIENTS WITH PRIMARY 
BILIARY CIRRHOSIS 
More than one vital organ can be transplanted if 
necessary. In our series, three patients who underwent 
liver transplantation for PBC also received a renal al-
lograft: two of them simultaneously and the third patient 
at 5 years after liver transplantation. The indications for 
the renal transplantation were nephrotic syndrome, in-
terstitial nephritis, and possible cyclosporine toxicity, 
respectively. All patients are alive, well, and with nor-
mally functioning grafts 2, 3, and 6 years after liver 
transplantation. 
The Cambridge Group have recently reported suc-
cessful heart, lung, and liver transplantation in a fatient 
with primary pulmonary hypertension and PBC. 2 It can 
be expected that the transplantation of various vital or-
gans in combination will be used increasingly for the 
treatment of patients with PBC who would not recover 
with liver transplantation alone. 
SUMMARY 
Liver transplantation is an effective treatment for 
PBe. The Pittsburgh experience is reported, with 1- and 
5-year survival of 75.62% and 70.71 %, respectively. 
Recurrence of PBC, when it occurs, has not been of 
clinical significance. 
Transplantation markedly improves chances for sur-
vival, an advantage that is demonstrable in all of the risk 
groups. Rehabilitation is achieved after transplantation 
in approximately 90% of the patients. 
Some clinical variables are associated with a poorer 
outcome and indicate the need for earlier treatment. 
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